ArticleBMC infectious diseases2025
Antimicrobial resistance profiles and detection of mecA, blaCTX-M-1, and blaSHV genes in bacteria among diabetic foot ulcer patients from selected referral hospitals in Uganda.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bacterial profile and antimicrobial resistance patterns of infected diabetic foot ulcers in low- and middle-income countries: a systematic review and meta‑analysis.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundEffective management of Diabetic foot ulcers (DFU) requires timely treatment of infections with appropriate antibiotics based on culture and susceptibility results. However, challenges in diagnostic testing persist and consequently, data on prevalent bacteria, their antimicrobial resistance profiles and genes remains scanty. This study profiled the prevalent bacteria in Diabetic foot infection (DFI), their antimicrobial susceptibility patterns, and associated resistance genes. METHODOLOGY: A multi-center cross sectional study was conducted from November 2021-January 2022, involving 117 patients with DFU, attending selected referral hospitals (Kiruddu, Jinja, Kampala International Teaching Hospital, Kitagata, Mbarara, Fort Portal and Hoima). Wound swabs were aseptically collected and placed in Stuart transport medium, then pre-enriched prior to inoculation onto Blood, MacConkey and Chocolate Agar to isolate aerobic microorganisms. Bacteria identification was based on colony morphology, Gram stain, conventional biochemical tests and Antibiotic susceptibility testing using Kirby-Bauer disk diffusion method were performed. Methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE) were identified phenotypically. mecA gene in selected MRSA, and blaCTX-M-1 and blaSHV-1 in ESBL-PE were detected using Uniplex PCR and electrophoresed using 1.5% agarose gel. Data was analyzed using MS Excel version 15 and Stata version 15 (Stata Corp®).
resultsMicrobiologically confirmed infection was observed in 89.7% (105/117) of DFU cases, yielding 144 bacterial isolates. Poly-microbial infections were detected in 23.8% of patients. Gram-positive bacteria accounted for 55.6% (80/144) of isolates. Staphylococcus aureus (36.1% (52/144)) and Proteus spp (13.9% (20/144)) were the most prevalent Gram-positive and Gram-negative bacteria, respectively. Notably, 98.6% (142/144) of the isolates were multidrug-resistant organisms (MDR). Staphylococcus aureus sensitivity was highest for Gentamycin and Ciprofloxacin (48% each) and lowest for Cefoxitin (2%). Proteus spp sensitivity was highest for Imipenem (87%) and lowest for Tetracycline, Ampicillin and Amoxiclav (0%). mecA gene was identified in 56% (5/9) of MRSA. Among the selected MDR Gram-negative isolates, 60% had blaCTX-M-1, 20% had blaSHV and both blaCTX-M-1 and blaSHV in one Klebsiella pneumoniae.
conclusionThe high prevalence of MDR bacteria in DFI underscores the need for culture and sensitivity testing-guided treatment. Detection of resistance genes calls for sustained surveillance efforts, stringent infection prevention and control, and alternative therapy exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.